1. South Korea Stocks

  2. •

    Technology services

  3. •

    Packaged software
VUNO Inc.

VUNO Inc.

KKRX:338220
5,910.00
KRW
-200.00
(-3.27%)
-770.77EPS
107.39BMarket Cap
Nov 17Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
18.08
18.26
140.9
207.59
730.67
1,140.11
1,873.87
2,490.2
2,158.81
Basic EPS, GAAP
-1,263
-666
-1,245
-1,806
-1,383
-1,342
-943
-413
-789.31
Free Cash Flow per Basic Share
-410.4
-628.95
-938.82
-1,515.63
-1,465.36
-1,368.21
-866.49
-410.57
-795.14
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
6.59
Book Value per Share
1,222.59
603.6
-405.7
2,015.55
1,627.72
365.42
2,198.66
2,579.27
2,548.77
Tangible Book Value per Share
1,216.96
586.19
-446.64
1,962.12
1,569.98
307.2
2,136.44
2,504.95
2,449.39
Basic Weighted Avg Shares
5
9
9
11
11
12
14
14
14
Sales/Revenue/Turnover
82
162
1,257
2,248
8,275
13,276
25,869
34,848
30,216
Operating Margin (%)
-3,258.31
-3,714.89
-773.27
-792.42
-185.71
-118.08
-48.13
-14.16
-31.95
Depreciation Expense
158
411
700
897
1,372
1,418
1,529
1,675
1,871
Net Income, GAAP
-5,752
-5,913
-11,109
-19,556
-15,662
-15,627
-13,018
-5,780
-11,048
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-6,984.29
-3,647.52
-883.59
-869.96
-189.28
-117.71
-50.32
-16.58
-36.56
Working Capital
11,191
3,877
-5,118
18,278
9,735
3,479
24,418
25,508
25,958
LT Debt
187
104
- -
3,171
2,327
4,972
1,814
28
11
Total Equity
10,976
5,419
-3,642
22,592
18,692
5,019
30,694
36,115
35,687
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-72.13
- -
- -
-76.19
-132.85
-72.94
-17.3
-35.5

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
7,624
6,625
6,038
LT Borrowings
- -
- -
- -
LT Finance Leases
28
17
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
312,941
216,048
107,394

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
37,931
42,590
36,570
Cash, Cash Equivalents & STI
31,124
36,388
30,957
Accounts Receivable, Net
4,272
3,843
3,532
Inventories
247
276
318
Total Current Liabilities
12,424
11,984
10,612
Payables & Accruals
- -
- -
- -
ST Debt
7,624
6,625
6,038
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-56.3%
17.66%
Free Cash Flow
- -
3.23%
-51.97%
Net Income, GAAP
- -
-3.28%
-55.61%
Sales/Revenue/Turnover
- -
107.38%
34.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,538
6,390
6,865
7,076
25,869
2025
7,538
9,254
10,824
7,232
34,848
2026
6,050
6,111
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-284
-234
-207
-220.55
-943
2025
-235
-58
73.86
-193.54
-413
2026
-284.82
-385
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
0.34
6.25
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ye-Ha Lee
Full Time Employees
165
Sector
Technology services
Industry
Packaged software
Address
507, Gangnam-daero Seoul SL South Korea 06536
IPO Date
Feb 26, 2021
Website
vuno.co
Similar Companies
Microsoft Corporation (NASDAQ:MSFT)
Palantir Technologies Inc. (NASDAQ:PLTR)
Nebius Group N.V. (NASDAQ:NBIS)
Oracle Corporation (NYSE:ORCL)
CoreWeave, Inc. (NASDAQ:CRWV)
ServiceNow, Inc. (NYSE:NOW)
Business
Vuno Inc. (338220.KQ) develops and commercializes artificial intelligence-based medical solutions that analyze medical imaging, biosignals, pathology slides, and speech data to assist in disease diagnosis and patient monitoring. Founded in 2014 and headquartered in Seoul, South Korea, the company offers core products under the VUNO Med brand, including VUNO Med-Chest X-ray, an AI-based screening solution for thoracic abnormalities on chest radiographs; VUNO Med-Fundus AI, a screening tool detecting essential retinal disease findings; VUNO Med-DeepBrain, a brain parcellation and quantification system supporting degenerative brain disease assessment on MR images; VUNO Med-DeepCARS, a vital signs analysis device predicting cardiac arrest risk within 24 hours for general ward patients; and VUNO Med-BoneAge, diagnostic software for bone age assessment; as well as VUNO Care-HATIV, a platform for personal health and chronic disease management. Vuno operates primarily in the medical AI sector, serving hospitals and healthcare providers with solutions deployed in South Korea and expanding internationally through CE-marked products. In recent developments, the company reported profitability in Q3 2025 driven by DeepCARS growth, with cumulative revenue for the first nine months exceeding full-year 2024 totals; partnered with European firms to advance DeepCARS market entry; secured approval for an AI tool detecting kidney disease from heart signals; and sold its chest CT AI business (Med-LungCT) to Coreline Soft for $2.3 million in early 2025 while acquiring a 3.23% stake in the buyer to support Japanese market expansion.